Q-omics provides the consensus-scored KRT4 profile across patient tissues and cancer cell-line models. KRT4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KRT4 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, KRT4 RNA expression shows 9,393 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, HNSC, and TGCT as cancer lineages where KRT4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT4 survival associations across molecular data types. KRT4 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT4 RNA expression–survival associations across cancer types. High KRT4 expression shows unfavorable associations in KIRC, OV, ACC, COAD, SKCM and CHOL. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KRT4 RNA expression.
This table summarizes KRT4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for KRT4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT4 shows lower tumor expression in HNSC, LUAD, LUSC and PRAD and higher tumor expression in COAD and BLCA. The HNSC box plot shows higher KRT4 RNA expression in normal versus tumor tissue (log2 FC = −7.559, t-test p < 0.001).
This table shows molecular features associated with KRT4 in patient tissues and cancer cell lines. In patient samples, KRT4 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, KRT4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BLOOD_Lymphoma.
